Hosted on MSN

17 Causes of Scabs on the Scalp

Scabs on the scalp can come from dandruff, acne, or contact dermatitis. Treating scalp conditions might involve medicated shampoos or prescription medications. Avoid products that cause irritation, ...
Medical Dialogues

Real-World Evidence Supports Dupilumab in Pediatric and Adult head and neck atopic dermatitis Patients: Study

Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...
Healio

Head and neck atopic dermatitis improves with upadacitinib treatment

Please provide your email address to receive an email when new articles are posted on . Patients with head and neck AD experienced greater improvement with upadacitinib than placebo. EASI, DLQI and ...
Seeking Alpha

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement

Primary efficacy and safety results from these ongoing pivotal studies have been previously reported: https://rb.gy/oqscek. "Despite taking steps to manage their condition, many patients with atopic ...
Benzinga.com

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib (Rinvoq, 15 mg once daily starting ...
Nasdaq

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

WESTLAKE VILLAGE, Calif. and ORLANDO, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...
Seeking Alpha

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic ...

NORTH CHICAGO, Ill., April 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study ...
Oklahoma's News

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement

NORTH CHICAGO, Ill., Sept. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The ...